(Total Views: 393)
Posted On: 02/23/2020 2:51:47 PM
Post# of 154888
Re: crazyjogger925 #19123
It's about having enough data to fit the FDA's guidelines.
The struggle with cancer indications is likely going to be having data that's comprehensive enough.
In my experience the best rule to remember is that everything takes longer than expected (obviously the BLA is a prime example).
The struggle with cancer indications is likely going to be having data that's comprehensive enough.
In my experience the best rule to remember is that everything takes longer than expected (obviously the BLA is a prime example).
(0)
(0)
